📰 Narcolepsy Type News
Page 2 - Narcolepsy Type News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Narcolepsy Type. Real-time updates on events, politics, business and more.
October 25, 2023
- Preclinical data demonstrated significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 - ORX750 advancing in IND-enabling studies; Clinical proof...
August 24, 2023
S.W. Black, T. Steinfeld, K. Gibson, G.R. Ott, E. Ratti, D. Grainger, M.A. Accardi, D.S. Hartman Centessa Pharmaceuticals, Inc., Boston, MA, United States, Centessa...
August 9, 2023
-- Successfully commenced U.S. commercial launch of LUMRYZ™-- -- Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through May 1, 2030 -- -- Significant early progress on payor coverage, prescriber certifications and patient enrollments -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to tra...
July 26, 2023
Trial Was Stopped Due to Hepatotoxicity and Consequently TAK-994 Program Terminated for Further Development In Patients with Narcolepsy Type 1, Oral Orexin Receptor 2 Agonist Demonstrated...
June 17, 2023
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) and Dermata Therapeutics (NASDAQ:DRMA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Profitability This table compares Centessa Pharmaceuticals and Dermata Therapeutics’ […]
June 10, 2023
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) and Dermata Therapeutics (NASDAQ:DRMA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends. Earnings & Valuation This table compares Centessa Pharmaceuticals and […]
March 27, 2023
Patients treated with Mazindol ER in the randomized Phase 2 trial showed continued improvement after rolling over into the open label extension (OLE) studyPatients treated with placebo in the randomized
May 19, 2022
Merrimack Pharmaceuticals (NASDAQ:MACK – Get Rating) and Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability. Institutional & Insider Ownership 55.9% of Merrimack Pharmaceuticals shares […]
March 30, 2022
Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update
March 30, 2022
- Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones - - SerpinPC registration studies planned to begin in 2H 2022 following